Che-kai K. Tsao

Oncology
450 Lakeville Road
New Hyde Park, NY 11042

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 81 publications

Efficacy of PARP inhibitor and immune checkpoint inhibitor combination therapy in PD-L1-negative cancers: a systematic review and meta-analysis.

Efficacy of PARP inhibitor and immune checkpoint inhibitor combination therapy in PD-L1-negative cancers: a systematic review and meta-analysis.

Journal: Immunotherapy
Published: August 25, 2026

CLO26-075: Are PARP Inhibitors Effective Beyond Homologous Recombination Repair-Deficiency in Castration-Resistant Prostate Cancer? A Meta-Analysis.

CLO26-075: Are PARP Inhibitors Effective Beyond Homologous Recombination Repair-Deficiency in Castration-Resistant Prostate Cancer? A Meta-Analysis.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: April 30, 2026

CLO26-075: Are PARP Inhibitors Effective Beyond Homologous Recombination Repair-Deficiency in Castration-Resistant Prostate Cancer? A Meta-Analysis.

CLO26-075: Are PARP Inhibitors Effective Beyond Homologous Recombination Repair-Deficiency in Castration-Resistant Prostate Cancer? A Meta-Analysis.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: March 30, 2026

External control arms can validate treatment efficacy in single-arm studies.

External control arms can validate treatment efficacy in single-arm studies.

Journal: Journal of the National Cancer Institute
Published: March 24, 2026

Long-Term Survival Outcomes of Immune Checkpoint Inhibitor-based Combination Therapies in Favorable-Risk Metastatic Renal Cell Carcinoma: An Updated Pairwise and Network Meta-Analysis.

Long-Term Survival Outcomes of Immune Checkpoint Inhibitor-based Combination Therapies in Favorable-Risk Metastatic Renal Cell Carcinoma: An Updated Pairwise and Network Meta-Analysis.

Journal: Clinical genitourinary cancer
Published: March 09, 2026

The Role of Gut Microbiome in Prostate Cancer: Current Evidence and Emerging Opportunities.

The Role of Gut Microbiome in Prostate Cancer: Current Evidence and Emerging Opportunities.

Journal: Cancers
Published: February 03, 2026

Clinical utility of tumour-informed circulating tumour DNA in patients with testicular cancer.

Clinical utility of tumour-informed circulating tumour DNA in patients with testicular cancer.

Journal: BJU international
Published: October 07, 2025

Overcoming Immune Evasion in the Prostate Tumor Microenvironment: Novel Targeted Strategies to Improve Treatment Outcomes.

Overcoming Immune Evasion in the Prostate Tumor Microenvironment: Novel Targeted Strategies to Improve Treatment Outcomes.

Journal: Cancers
Published: August 29, 2025

A Pilot Study of the Combination of 5-Azacitidine and All-trans Retinoic Acid in Biochemically Recurrent Prostate Cancer.

A Pilot Study of the Combination of 5-Azacitidine and All-trans Retinoic Acid in Biochemically Recurrent Prostate Cancer.

Journal: medRxiv : the preprint server for health sciences
Published: August 20, 2025

Can PARP Inhibitors Benefit Patients with Homologous Recombination Repair-Proficient Castration-Resistant Prostate Cancer? A Meta-analysis.

Can PARP Inhibitors Benefit Patients with Homologous Recombination Repair-Proficient Castration-Resistant Prostate Cancer? A Meta-analysis.

Journal: Targeted oncology
Published: August 19, 2025

Artificial intelligence in oncology: promise, peril, and the future of patient-physician interaction.

Artificial intelligence in oncology: promise, peril, and the future of patient-physician interaction.

Journal: Frontiers in digital health
Published: May 24, 2025

A multi-perspective study assessing Black and African American participation barriers in prostate cancer clinical trials.

A multi-perspective study assessing Black and African American participation barriers in prostate cancer clinical trials.

Journal: Future oncology (London, England)
Published: February 24, 2025
Showing 1-12 of 81

Last Updated: 09/26/2026